News
-
-
COMMUNIQUÉ DE PRESSE
Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
Immunic announces positive outcome of interim analysis of Phase 3 ENSURE Program for vidofludimus calcium in RMS. Trials recommended to continue unchanged till 2026 -
-
-
COMMUNIQUÉ DE PRESSE
Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
Immunic presents key Vidofludimus Calcium data at the 40th Congress of ECTRIMS, highlighting its therapeutic potential in Multiple Sclerosis. Immunic, Inc. (Nasdaq: IMUX) showcases findings at the conference in Copenhagen, Denmark -
-
-
COMMUNIQUÉ DE PRESSE
Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
Immunic announces enrollment of the first patient in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium for Post COVID Syndrome. Study aims to suppress EBV reactivation and fatigue symptoms -
-
